Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $178.3 million.

  • Tg Therapeutics' Cash & Equivalents fell 894.79% to $178.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.3 million, marking a year-over-year decrease of 894.79%. This contributed to the annual value of $179.9 million for FY2024, which is 9357.39% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Cash & Equivalents is $178.3 million, which was down 894.79% from $278.9 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Cash & Equivalents high stood at $471.5 million for Q1 2021, and its period low was $61.5 million during Q1 2023.
  • For the 5-year period, Tg Therapeutics' Cash & Equivalents averaged around $195.4 million, with its median value being $178.3 million (2025).
  • Per our database at Business Quant, Tg Therapeutics' Cash & Equivalents soared by 80586.92% in 2021 and then plummeted by 6689.45% in 2023.
  • Over the past 5 years, Tg Therapeutics' Cash & Equivalents (Quarter) stood at $298.9 million in 2021, then crashed by 65.77% to $102.3 million in 2022, then fell by 9.16% to $92.9 million in 2023, then skyrocketed by 93.57% to $179.9 million in 2024, then decreased by 0.89% to $178.3 million in 2025.
  • Its last three reported values are $178.3 million in Q3 2025, $278.9 million for Q2 2025, and $276.2 million during Q1 2025.